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Background and PurposezzThe goal of this study was to estimate the efficacy and safety of the 
rivastigmine transdermal patch in patients with probable Alzheimer’s disease (AD) who cannot 
tolerate or do not respond to oral cholinesterase inhibitors (ChEIs).
MethodszzA 24-week, prospective, open-label, single-arm, multicenter study was conducted from 
June 2009 to June 2010 in patients with probable AD. The enrolled patients had either a poor re-
sponse or a decline in global function after treatment with oral ChEIs, or they were not able to 
tolerate treatment with oral ChEIs due to adverse events such as nausea or vomiting. A poor re-
sponse was defined as a decrease of at least 2 points on the Korean version of the Mini-Mental 
State Examination (K-MMSE) within the previous 6 months (the decline in global function was 
determined by the investigator or caregiver). The efficacy of treatment was assessed using a fol-
low-up Clinical Global Impression of Change (CGIC) assessment and K-MMSE conducted after 
24 weeks, and safety was measured by the occurrence of adverse events and patient disposition.
ResultszzIn total, 164 patients aged 74.7±7.52 years (mean±SD) and with 5.12±3.64 years of 
education were included. The study was completed by 70% of the patients (n=116), with 12.2% 
discontinuing due to adverse events. The most frequently reported adverse events (11%) were skin 
lesions, such as erythema or itching, followed by gastrointestinal problems (1.2%). Either an im-
provement or no decline in CGIC scores was reported for 82% of the patients.
ConclusionszzThe immediate switching of patients from an oral ChEI to the rivastigmine trans-
dermal patch without a washout period was safe and well tolerated by the probable-AD patients in 
this study.
  J Clin Neurol 2011;7:137-142
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Introduction
Cholinesterase inhibitors (ChEIs) are widely used in clinical 
practice for the symptomatic treatment of mild-to-moderate 
Alzheimer’s disease (AD) and Parkinson’s-disease dementia. 
ChEIs are effective in improving the cognitive and global func-
tioning of AD patients, and are the main pharmacological in-
tervention in the clinical management of the disease.
1-3 How-
ever, the incidence of adverse events associated with oral Ch-
EIs, and particularly those of nausea and vomiting, increases 
with the administered dose, which can make it difficult to achi-
eve and maintain high therapeutic doses in clinical practice.
4-6
The recently developed rivastigmine transdermal patch re-
presents a next generation of acetylcholinesterase treatments, 
and it is now available in many countries.
7 By delivering the 
drug through the skin, directly into the bloodstream, transder-
mal patches avoid first-pass effects and result in reduced rates 
of nausea and vomiting compared with oral ChEIs.
8,9 How-
ever, the different pharmacologic characteristics of the three 
commonly used ChEIs may influence the treatment responses 
of individual patients. Some AD patients do not show impro-
vements in cognitive function and quality of life, even with 
prolonged intake of a maintenance dosage of ChEIs. Consis-
tent with these observations, previous studies have shown that 
AD patients who have an inadequate response or intolerance 
of one ChEI may experience symptom improvement after sw-
itching to another ChEI.
10-12 The goal of this study was to 
elucidate the efficacy, safety, and tolerability of switching 
from oral ChEI treatment to the rivastigmine transdermal 
patch in patients with probable AD who had experienced ad-
verse reactions or poor responses to oral ChEI treatment.
Methods
Patients
Patients meeting the inclusion criteria for this study were wo-
men or men aged 50-85 years with a diagnosis of dementia 
of the Alzheimer’s type, according to the criteria of the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth Edi-
tion Text Revision, and probable AD, according to the criteria 
of the National Institute of Neurological and Communicative 
Disorders and Stroke and the AD and Related Disorders As-
sociation
13 Eligible patients had mild-to-moderate disease, 
which was confirmed by a score on the Korean version of the 
Mini-Mental State Examination (K-MMSE) of 10-26.
14 Each 
patient underwent a comprehensive evaluation with a neurolo-
gical examination and appropriate laboratory tests.
15 Patients 
had to have received treatment with oral ChEIs (donepezil, ga-
lantamine, or rivastigmine capsules) for a minimum of 3 mon-
ths prior to baseline, and in the investigator’s clinical judgment 
must have been responding poorly to or been deteriorating on 
their current treatment.
The patients were assigned to either a poor-response group 
or an adverse-events group. The poor-response group compris-
ed patients with a loss of at least 2 points on the K-MMSE 
within the previous 6 months or a decline in the activities of 
daily living (ADL) or global functioning, as determined by 
the investigator or caregiver. All patients were required to 
have a caregiver in contact with them for a minimum of 3 
days/week and who was available to accompany them on all 
visits associated with the study. The adverse-event group was 
classified as patients who had experienced adverse reactions 
such as nausea or vomiting after the administration of oral 
ChEIs and who could no longer take oral ChEIs.
Exclusion criteria included an advanced, severe, or unstable 
medical condition of any type that could interfere with the ev-
aluation and any condition other than AD that could explain 
the dementia. Patients were also excluded if they had experi-
enced any cerebrovascular accidents within 6 months prior to 
baseline, a current diagnosis of active, uncontrolled seizure dis-
order, or any psychiatric diagnosis that might interfere with 
the response of the patient to a clinical trial.
Prior to participation in the study, patients provided written 
informed consent once they were determined by the investi-
gator to be mentally competent. If the patient was not able to 
provide written informed consent, this was obtained from the 
caregiver or an authorized representative on the patient’s be-
half. The study was conducted according to the ethical prin-
ciples of the Declaration of Helsinki, as revised in 2000.
Study design
This was a prospective, 24-week, open-label, multicenter stu-
dy conducted in South Korea from June 2009 to June 2010. 
After assessments of eligibility for this study, patients under-
went baseline efficacy and safety assessments. They were then 
assigned to either the poor-response or adverse-events groups. 
Screening was performed at baseline (visit 1) and at visits 2, 
3, and 5, which occurred during weeks 4, 12, and 24, respec-
tively. All patients were started on the 5 cm
2 rivastigmine tr-
ansdermal patch, and the first patch was applied between 24 
and 36 h after the last dose of oral ChEIs. If the patient had 
already discontinued oral ChEIs prior to the baseline visit, the 
time between the last dose of oral ChEI and the first applica-
tion of the rivastigmine transdermal patch could not exceed 
7 days. If the patient demonstrated good tolerability to the 
initial 5 cm
2 patch, the rivastigmine patch dose was increased 
to 10 cm
2 after 4 weeks. If the target dose was not achieved 
during the titration period, the investigator could resume ti-
tration during the maintenance period. Patients were main-
tained at their highest well-tolerated dose until the end of the  Han HJ et al.
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study. The patch was applied by caregivers to clean, dry, and 
hairless skin on the patient’s upper back every morning, and it 
was worn for 24 h. Normal activities, including bathing, were 
permitted. In order to minimize any skin irritation, the appli-
cation site of the patch was alternated daily between the left 
and right sides.
Assessment
An interview for the Clinical Global Impression of Change 
(CGIC) scale (the primary efficacy measure) was performed at 
baseline, and changes from baseline were assessed at weeks 
12 and 24 (or at early termination).
16 The CGIC was rated on 
a 7-point scale ranging from 1 (very much improved) to 7 (very 
much worse), with 4 indicating no change. The CGIC score 
was used to determine the primary efficacy variable, which 
was the percentage of patients receiving treatment with riv-
astigmine (i.e., who had achieved a score of ≤4) at 24 weeks. 
Responders to treatment were defined as patients with a CGIC 
score of 4 or less and poor responders were defined as those 
who had a CGIC score of 5-7. According to the protocol, each 
patient was assessed by the same clinician who interviewed 
them at their baseline visit. For all ratings of change from ba-
seline on the CGIC, the clinician relied on information ob-
tained from the patient at the baseline visit, as well as clinical 
information obtained throughout the study period. The clini-
cian did not have access to any efficacy data collected during 
the current study visit. For this reason, the CGIC was rated pri-
or to all other efficacy evaluations.
The K-MMSE, the Korean Instrumental Activities of Daily 
Living (K-IADL), and the Clinical Dementia Rating-Sum of 
Box (CDR-SB) were used as secondary outcome measures to 
assess the effects of the treatment with the rivastigmine trans-
dermal patch on cognitive functioning and ADL.
14,17,18 These as-
sessments were performed at baseline, and weeks 12 and 24.
Tolerability and safety evaluations were assessed at each 
visit during the treatment period through the collection of in-
formation concerning adverse events, including serious ad-
verse events. Vital signs and body weight were recorded at 
each visit. Routine laboratory tests were performed at base-
line; postbaseline laboratory tests were not performed rou-
tinely unless any abnormal clinical laboratory findings devel-
oped and induced clinical signs or symptoms that were con-
sidered clinically significant or that required therapy; these 
were recorded as adverse events. Skin irritation was evaluated 
at every visit by the investigator based on inspection of the 
skin at the site of application. Skin irritation also was assess-
ed by the caregiver, who provided a summary irritation rating.
Statistical methods
All patients who took at least one dose of study medication 
were included in the safety analysis, which those patients who 
additionally provided a valid baseline and at least one post-
baseline measurement were included in the intent-to-treat 
population. Statistical analyses of efficacy outcome measures 
were performed on the final group of enrolled cases of the stu-
dy population. The primary analysis time point was week 24, 
and changes in efficacy measures from baseline were tested us-
ing a paired t-test; the level of statistical significance was set 
at p<0.05. The 95% confidence interval corresponds to the 
percentage of patients who demonstrated an improvement or 
no change from baseline (as assessed using CGIC scores).
Results
Study population
Of the 164 patients who were enrolled in this study, 116 pa-
tients (70.5%) completed all 24 weeks (Fig. 1). The patients 
were divided into the poor-responder group (75/116, 64.7%) 
and the adverse-events group (41/116, 35.3%). The patients’ 
baseline demographic and background characteristics are sum-
marized in Table 1. There were no significant differences be-
tween the poor-responder group and the adverse-events group 
164 patients with probable AD from 9 centers
Poor response group
(n=75, 64.7%)
Adverse events group
(n=41, 35.3%)
Skin problems (n=18)
Follow up loss (n=18)
Withdrawal of consent (n=5)
Protocol violation (n=5)
Gastrointestinal upset (n=2)
Exelon patch 5 cm2 for 4 weeks → patch 10 cm2 for 20 weeks
Complete trial (n=116, 70.5%)
Fig. 1. Study flowchart for patients with probable Alzheimer’s dis-
ease.
Table 1. Demographic findings and clinical characteristics of the 
poor-responder and adverse-events groups in patients with prob-
able Alzheimer’s disease at baseline
Total group 
(n=116) 
Poor responder 
group (n=75)
Adverse events 
group (n=41)
Age (yr) 74.7±7.52  74.5±7.2  75±7.5
Gender (M/F) (55/109) (22/53) (9/32)
Education (yr) 5.12±3.64 05.4±5.2 4.6±3.7
K-MMSE 17.2±5.46 17.54±5.66 16.6±5.68
CDR-SB 6.21±3.82 05.88±4.33 6.81±4.24
K-IADL 01.3±0.96 01.33±0.95 1.33±0.92
K-MMSE: Korean version of Mini-Mental State Examination, CDR-
SB: Clinical Dementia Rating-sum of box, K-IADL: Korean version 
of Instrumental Activities of Daily Living.An Open-Label Study, Multicenter Study
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at baseline.
Efficacy
At week 24, approximately 82.8% (96/116) of the patients de-
monstrated either an improvement or no further deterioration 
in global functioning, as assessed by the CGIC rating of change 
from baseline (CGIC scores ≤4; Fig. 2). Similar results were 
observed for the two groups, with 82.7% (61/75) of the poor-
responder group and 83% (34/41) of the adverse-events group 
demonstrating either an improvement or no further deteriora-
tion in global functioning as assessed by the CGIC rating of 
change from baseline (Fig. 3). Of the 116 patients with K-MM-
SE scores of 10-26, 64.3% showed an increase or a steady 
state from baseline at week 24, but those changes did not dif-
fer significantly from baseline (p>0.05). The change in K-
MMSE score at week 24 relative to baseline was 0.42±0.8 
(mean±SD). The K-IADL and CDR-SB scores of the entire 
cohort did not change significantly between baseline and week 
24. There were no statistically significant differences in the 
subgroup analysis (poor-response and adverse-events groups) 
of the secondary efficacy measures. The changes from baseline 
for the secondary efficacy variables are given in Table 2.
Safety and tolerability
Forty-eight patients (29.5%) left the study due to adverse ev-
ents (n=20, 12.2%), follow-up loss (n=17, 10.5%), poor com-
pliance (n=6, 3.7%), or protocol violation (n=5, 3%). The 
most common adverse event that resulted in discontinuation 
was skin lesions, such as erythema or an itching sensation, wh-
ich occurred in 11% of the patients; there were no reported 
cases with serious skin problems. The next common adverse 
event was gastrointestinal problems, such as nausea, vomiting, 
or anorexia, which occurred in 1.2% of the patients. The most 
frequently reported adverse events are summarized in Table 3.
Discussion
The results of this multicenter study suggest that immediate 
switching from oral ChEIs to the rivastigmine transdermal 
patch is safe and well tolerated by patients with AD. Almost 
80% of this population of patients who were not responding 
adequately to oral ChEIs showed either an improvement or 
no further deterioration in global functioning, as assessed by 
the CGIC. The K-MMSE scores increased slightly in the ov-
Fig. 2. Clinical Global Impression of Change (CGIC) scores at 
week 24 (n=116). 1: very much improved, 2: much improved, 3: 
slightly improved, 4: no change, 5: slightly worse, 6: much worse, 
7: very much worse.
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Fig. 3. CGIC scores in the poor-responder (n=75) and adverse-
events (n=41) groups at week 24. CGIC: Clinical Global Impres-
sion of Change.
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Table 2. Changes from baseline at week 24 for secondary efficacy measures among patients with probable Alzheimer’s disease
Outcome 
measures
              Changes from baseline at week 24
Totalgroup (n=116) Poorresponder group (n=75) Adverse events group (n=41) p value
K-MMSE 00.4±0.66 0.44±0.70 0.55±0.73 p>0.05
CDR-SB 0.01±0.16 0.14±0.39 -0.23±0.14 p>0.05
K-IADL 0.06±0.07 0.03±0.01 0.04±0.11 p>0.05
K-MMSE: Korean version of the Mini-Mental State Examination, CDR-SB: Clinical Dementia Rating-Sum of Box, K-IADL: Korean version 
of the Instrumental Activities of Daily Living.
Table 3. Adverse events reported during the 24-week study peri-
od in patients with probable Alzheimer’s disease
Adverse events Number (%) of patients
Skin problems 18 (11)
Follow up loss 18 (11)
Withdrawal of consent  5 (3)
Protocol violation 5 (3)
Gastrointestinal upset 2 (1.2) Han HJ et al.
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erall population, but this increase was not statistically signifi-
cant. The results of this study concur with those of previous 
clinical trials conducted in patients who were switched from 
donepezil to rivastigmine.
12,19,20 In an open-label clinical trial, 
patients were switched from donepezil to rivastigmine due to 
a lack of efficacy (55%) or adverse events (45%), and nearly 
half of them demonstrated improvement in cognition while 
receiving rivastigmine treatment.
12
A recent prospective open-label multicenter study was con-
ducted in which 201 patients who failed previous treatment 
with donepezil (n=116, 57.7%) or galantamine (n=84, 41.8%) 
were treated with rivastigmine capsules (3-12 mg/day) for 16 
weeks. Of these, 93 patients (46.3%) responded to rivastig-
mine as evidenced by improved (28.4%) or stabilized (17.9%) 
scores on the Mini-Mental State Examination scores.
21 How-
ever, our study showed marked improvements on the CGIC 
and fewer adverse events during the 24 weeks of treatment 
compared to other clinical studies. We believe that this was 
because the oral ChEIs were switched to the rivastigmine tr-
ansdermal patch rather than to capsules in our study. The riv-
astigmine patch was only recently developed and has been 
shown to provide smooth and continuous drug delivery throu-
gh the skin and into the bloodstream, avoiding first-pass ef-
fects in the gut and the liver, offering potential benefits over 
conventional oral administration in patients with AD.
9,22
The aforementioned studies and ours are limited by their 
open-label design and by the lack of prospective, objective, 
and quantitative information regarding the rate of deteriora-
tion before switching. A placebo group was not included in 
the study due to ethical concerns regarding not providing tr-
eatment to patients who were already poor responders to oral 
ChEIs. The lack of a control group and the absence of rando-
mization limit the conclusions that can be drawn from the 
study. However, there are several important clinical implica-
tions of the results reported here.
The first is that it is possible to switch patients from oral 
ChEIs to rivastigmine without a washout period. Immediate 
switching to the rivastigmine patch may be beneficial to pa-
tients in that it avoids the potential loss of therapeutic effects 
and decline in cognitive functioning associated with a discon-
tinuation of treatment. Our results suggest that most patients 
who no longer respond to oral ChEIs will still show stabili-
zation or improvement in overall global functioning or be-
havior with the rivastigmine patch. This improvement or sta-
bilization, as assessed with the CGIC, was even observed in 
most of the patients who had experienced a prior deteriora-
tion of 2 points or more on the K-MMSE during treatment 
with oral ChEIs.
The second important clinical implication is that the riv-
astigmine patch demonstrated good skin tolerability through-
out the clinical trial phase, with any reactions usually being 
mild in severity. In one open-label extension study of the riv-
astigmine patch, skin tolerability was good in over 90% of 
all patients, with the most commonly reported skin irritation 
being erythema and pruritus (7.7% and 5.6%, respectively). A 
small proportion of patients (3.7%) withdrew due to applica-
tion-site skin reactions.
22 The results of our clinical trial dem-
onstrated that 18 (11%) of the enrolled subjects experienced 
skin problems, but not serious skin reactions. The next most 
common adverse event was gastrointestinal side effects, such 
as nausea or vomiting. However, these adverse events were ge-
nerally manageable and led to fewer than 2% of the patients 
discontinuing the treatment.
In summary, the results of this study suggest that poor re-
sponders to oral ChEIs will experience symptom improve-
ment or stabilization when switched to the rivastigmine tr-
ansdermal patch. Furthermore, an immediate switch from 
oral ChEIs to the rivastigmine transdermal patch was safe and 
generally well tolerated by most of our patients with proba-
ble AD. Given the importance of the clinical implications of 
this study, further randomized, controlled studies should be 
undertaken to determine the potential clinical benefits of sw-
itching to the rivastigmine transdermal patch for patients who 
are not responding to oral ChEIs.
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